# Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

> **NCT05786430** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yonsei University** · enrollment: 87 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Lazertinib/Pemetrexed/Carboplatin

## Key facts

- **NCT ID:** NCT05786430
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-07
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786430, "Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05786430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*